Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 17INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 2

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Chemoembolization, Therapeutic × Clear all
NCT04231929 2022-03-28

BIOPEARL-FIRST

Terumo Europe N.V.

Phase NA Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT02548780 2020-01-27

LifePearl-Doxo Pharmacokinetic (PK) Study

Terumo Europe N.V.

Phase NA Completed
15 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡